Professional Education

Recent Updates

Published:

Mar 22, 2017

Donor Selection, Transmissible Disease Testing and Pathogen Reduction

Chapter 6

All blood transfused in Canada is collected from volunteer donors. To ensure the safety of the blood products, donors are carefully screened against an extended list of eligibility criteria and their donated blood products are tested for transfusion-transmissible diseases. Donor eligibility criteria also reduce potential health risks for the donor. This chapter describes the donor selection process, the pathogen testing done on blood products, and the pathogen inactivation processes that can further reduce the potential risk of transfusion-transmitted diseases.

Twitter Facebook LinkedIn Forward

Published:

Mar 31, 2017

Fractionated Blood Products and Associated Pathogen Safety

Chapter 7

Background

Originally all plasma fractionation products were derived from pooled human plasma. Increasingly, many plasma proteins are manufactured by biotechnology as recombinant proteins, without need of donated plasma; depending on the particular plasma protein product, a recombinant or a fractionated product or both are available in Canada.

This Chapter presents in general terms the various methods and principles by which plasma protein products are manufactured for use in patients. It is complemented by Chapter 3, 4, 5 and 6 of this Guide.

Twitter Facebook LinkedIn Forward

Published:

May 31, 2017

Preoperative Autologous Donation

Chapter 16

This chapter focuses on preoperative autologous donation (PAD). There are other types of autologous blood use (e.g. acute normovolemic hemodilution and intraoperative and postoperative blood salvage) which are not discussed in this chapter.

PAD refers to the donation of blood by a patient for his/her own future use; generally this is for a scheduled elective surgery. The top three procedures associated with a request for a PAD are total hip replacement, total knee replacement and hysterectomy.

In most cases, allogeneic blood transfusions are a safe and available option. Autologous and directed donations should be confined to circumstances of rare blood types or plasma protein deficiencies in which allogeneic units may not meet patient needs. Rare blood types represent only a small number of autologous units collected each year.

Transplant Atlantic 2017

Twitter Facebook LinkedIn Forward

When

September 25, 2017 | 8:00AM to 4:00PM

Where

Lord Nelson Hotel, Halifax

Theme : “Breaking Down Barriers”
When : September 25, 2017 (8am - 16:00 pm)
Where : Lord Nelson Hotel, Halifax
Program : Program at a Glance Save the Date

Critical Care Canada Forum

Twitter Facebook LinkedIn Forward

When

October 2, 2017 | 8:00AM to October 5, 2017 | 5:00PM

Where

Toronto

The Critical Care Canada Forum 2017 is Canada's national critical care meeting. Held over 4 days, it focuses on clinicians, scientists, and leaders in critical care medicine, and attracts the best speakers worldwide. CCCF consists of superlative plenary talks, thematic sessions and posters, with exhibits that demonstrate the latest products and services.

Featuring internationally renowned experts; Darren Freed (Canada), Stephen Large (UK), Peter MacDonald (Australia), Paul Murphy (UK), and Robert TRuog (USA).